Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipopolysaccharide (LPS) and anionic lipids are essential structural components of the Gram-negative bacterial cell envelope [Raetz & Whitfield, 2002]. LPS, also known as endotoxin, constitutes the majority of the outer leaflet of the outer membrane and is critical for maintaining the structural integrity and permeability barrier of the bacterium [Silhavy et al., 2010]. Anionic lipids, such as phosphatidylglycerol and cardiolipin, are found in both the inner and outer membranes and contribute to the overall negative charge of the bacterial surface [Epand et al., 2016]. These molecules serve as primary targets for several classes of antibiotics, most notably the polymyxins, which bind to the Lipid A component of LPS and displace stabilizing divalent cations like Mg2+ and Ca2+ [Velkov et al., 2013]. This interaction leads to the disruption of the membrane, leakage of cellular contents, and ultimately bacterial cell death. Beyond their structural role, LPS is a potent inducer of the host immune response via the Toll-like receptor 4 (TLR4) pathway, making it a central player in the pathogenesis of sepsis and septic shock [Alexander & Rietschel, 2001].
Drugs like polymyxins bind to the negatively charged Lipid A of LPS and anionic phospholipids via electrostatic interactions, displacing divalent cations (Mg2+, Ca2+) that stabilize the membrane [Velkov et al., 2013]. This causes a detergent-like effect, increasing membrane permeability and leading to the leakage of cytoplasmic contents and cell death [Trimble et al., 2016].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide and anionic lipids (LPS).